🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Powerful talk by Rana McKay, MD, FASCO with an overview on #HIF2 inhibitors treatment landscape, #LITESPARK clinical trials comprehensive results and updates. Exciting data and future opportunities for #RCC therapy armentarium. #ASCO25 ASCO The ASCO Post Journal of Clinical Oncology Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO

Earlier today our journal editors shared lots of valuable info on “Publication 101: Peer Review & Becoming a Successful Author” in our #ASCO25 Trainee & Early Career Lounge & #ASCODailyNews EIC @neerajaiim was in #JCO Central for a meet & greet. Thank you to all who joined us!

Presented at #ASCO25 Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive #ProstateCancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes meetings.asco.org/abstracts-pres… The

Don’t miss the #IUCS25! 📅 Sept 4-5, Portsmouth & online 🎟️ Free in-person registration 📝 Abstracts & travel grants open until June 30! Join experts in #GUonc & get involved! Register ➡️ urologycancersummit.org/registration Submit abstracts ➡️ urologycancersummit.org/abstracts

Top #GUCancer Oncologists from ASCO 2025. Follow us for more #ASCO25 updates: t.ly/7TCD6 #LARVOL #GenitourinaryCancer #CancerResearch #Oncology #CancerData #ClinicalTrials #OncologyInsights #ASCO2025 | Toni Choueiri, MD | Neeraj Agarwal, MD, FASCO | Andrea Necchi | Tom Powles |

The highlight of #ASCO25 was the AMPLITUDE trial presented by AttardLab on PARPi in HRR altered mHSPC. Listen to our podcast discussing these practice-changing data! spotifycreators-web.app.link/e/77hbNX73YTb

The International Bladder Cancer Group (IBCG) is pleased to announce the #IBCG2025 Travel Award, designed to support outstanding fellows and early-career academic faculty who are committed to advancing the field of bladder cancer. For more information and to apply:

🚨 New findings in metastatic hormone-sensitive prostate cancer (#mHSPC)! 🚨 🔹 Over 12% of mHSPC patients harbor BRCA1/2 mutations, enriched in high-volume disease 🔹 Another 16% carry other homologous recombination repair (#HRR) gene alterations — overall HRR prevalence

Timely and much-needed recommendations from ASCO We hope academic medical centers implement them without delay—for the well-being of oncologists and the future of cancer care. ASCO Journal of Clinical Oncology OncoAlert Eric Winer, MD Clifford Hudis Julie Gralow Jame Abraham, MD, FACP Erika Hamilton, MD

#PERSIAN trial explores SBRT benefits in oligometastatic hormone-sensitive #ProstateCancer. Giulio Francolini Azienda Ospedaliero-Universitaria Careggi sits down with Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute to discuss SBRT added to ADT plus apalutamide in oligometastatic #HSPC. Preliminary analysis of 87 patients shows a

Comparing ARPI options across disease volume and metastatic timing in #mHSPC. Syed Arsalan Ahmed Naqvi and Irbaz Riaz MD,MS,MBI,PhD Mayo Clinic join Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute to discuss a 7,000-patient meta-analysis showing no major efficacy differences among abiraterone, apalutamide, enzalutamide &

Join our collaborators at VJ Oncology for a series of post #ASCO25 webinars on breast, skin, lung, genitourinary, and gastrointestinal cancers, hosted by renowned international experts. REGISTER HERE: 👉 bit.ly/4jtNGoi Eva M Ciruelos . Noemi Reguart Neeraj Agarwal, MD, FASCO

Dear Colleagues, A warm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Beautiful Lugano Switzerland🇨🇭April 30-May 2, 2026 👉REGISTER HERE: apccc.org/apccc-2026/ In an era of rapid innovation and expanding treatment options for advanced #ProstateCancer

Radiation therapy vs surgery outcomes in high-risk localized #ProstateCancer patients. SOUMYAJIT ROY RUSH Cancer Center joins Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute to discuss his systematic analysis of two major trials—CALGB 90203 (PUNCH) and RTOG 0521—to address the ongoing debate about

#ASCO25 GU #cancer highlights- pleased to comment in Doximity from AdventHealth Central Florida AdventHealth Yüksel Ürün Enrique Grande Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO Shilpa Gupta doximity.com/newsfeed/85023…

UCSD GU Medical Oncology is looking for the next academic medical oncologist to join our group! Amazing to see this program continue to blossom. The sky is the limit! ⁦Toni Choueiri, MD⁩ ⁦Neeraj Agarwal, MD, FASCO⁩ ⁦UroToday.com⁩ ⁦OncoAlert⁩ ⁦ apol-recruit.ucsd.edu/JPF04302

Recognizing Top Oncologists, Top Women Oncologists, and Rising Stars from ASCO 2025 at Times Square! Dr Amol Akhade | Paolo Tarantino | Aakash Desai, MD, MPH, FASCO | Stephen V Liu, MD | Hidehito HORINOUCHI | Toni Choueiri, MD | Yakup Ergün | Neeraj Agarwal, MD, FASCO | Andrea Necchi | Sharlene Gill, MD, MPH, MBA, FASCO | Aya Mohamed | MSc, MD 🎗 |

#IMPLEMENT study reveals barriers to treatment intensification in metastatic #ProstateCancer. Stacy Loeb, MD NYU Langone Health joins Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute to discuss barriers to treatment intensification in#mHSPC and the mixed-methods approach combining qualitative interviews with a

A non-androgen targeted approach might be an alternative in patients with metastatic castration resistant prostate cancer who have progressive disease with ARPI❓ CONTACT-02 Phase ⤵️ ✅Cabozantinib + atezolizumab significantly improved progression-free survival vs ARPI switch

Just in Clinical Cancer Research 👉Congrats Chadi Hage Chehade Umang Swami & GU Cancer Research Program @HuntsmanCancer team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 Flatiron Health Foundation Medicine Ryon Graf, PhD 👉 need to add PARPi 👉free link: bit.ly/3TsOw9i OncoAlert UroToday.com